Item 8.01 Other Events.

Enzon Pharmaceuticals, Inc. (the "Company") is filing this Current Report on Form 8-K for the purpose of providing stockholders with additional information regarding the tax characteristics of the Company's special dividend of $2.00 per share of common stock that was paid on December 21, 2012 to the Company's stockholders of record as of December 10, 2012 (the "Special Dividend"). $0.1851 per share of the Special Dividend is estimated to be a taxable dividend (with no effect on basis). The remaining $1.8149 per share of the Special Dividend is a reduction in the stock basis in each share. To the extent the tax basis in a share is less than $1.8149, the excess of $1.8149 over the basis in that share is recognized as capital gain.

A copy of the Internal Revenue Service Form 8937 for the Special Dividend has been posted on the "Investors and Media" page of the Company's website at http://investor.enzon.com/.

The Company does not provide tax advice. Stockholders should consult with their own tax advisors regarding the specific tax treatment of the special dividend that they received from the Company.